Table 1. Patient characteristics.
| Characteristic | Total (n=54) | GBC (n=13) | iCCA (n=35) | eCCA (n=6) |
|---|---|---|---|---|
| Males, n (%) | 27 (50.0) | 5 (38.5) | 19 (54.3) | 3 (50.0) |
| Age, median [range] | 58 [34–73] | 59 [48–67] | 58 [34–73] | 62 [60–67] |
| Prior surgery, n (%) | 18 (33.3) | 7 (53.8) | 6 (17.1) | 5 (83.3) |
| cTNM staging, n (%) | ||||
| III | 2 (3.7) | 0 | 2 (5.7) | 0 |
| IV | 52 (96.3) | 13 (100.0) | 33 (94.3) | 6 (100.0) |
| ECOG score, n (%) | ||||
| 0 | 41 (75.9) | 9 (69.2) | 27 (77.1) | 5 (83.3) |
| 1 | 13 (24.1) | 4 (30.8) | 8 (22.9) | 1 (16.7) |
| CA19-9 range, mean [range], U/mL | 559.6 [0.93 to >10,000] | 397.6 [0.93 to >2,312] | 532.5 [8.09 to >10,000] | 1,068.5 [10.57 to >2,917] |
GBC, gallbladder cancer; iCCA, intrahepatic cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; cTNM, Tumor, Nodes, Metastasis classification of staging; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19-9.